Clinical trials: Lymphatic Diseases
- Condition Lymphatic Diseases
- Funder type Industry (pharma, biotech, devices)
- Accepts healthy volunteers yes
Chronic Myeloid Leukemia, Gastrointestinal Stromal Tumor
A Clinical Trial to Compare the Pharmacokinetics of Imatinib Mesylate Tablet 400mg (1 Tablet) and Glivec Film-coated Tablet 100mg (4 Tablets)(Phase I)
1. Investigational Product 1. Imatinib mesylate tablet 400 mg 2. Glivec film-coated tablet 100 mg (Comparator) 2. Expected target disease 1. chronic myeloid leukemia 2. Gastrointestinal stromal tumors 3.
- Trial name
- NCT01751919
- Testing
- Imatinib mesylate tablet 400 mg, 1 Tablet, Glivec film-coated tablet 100 mg, 4 Tablets
- Where
- South Korea
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- Dong-A ST Co., Ltd.
Anaemia
Daprodustat Hepatic Impairment Study
Daprodustat (GSK1278863), is a small molecule currently in development for the treatment of anemia of chronic kidney disease (CKD).
- Trial name
- NCT03223337
- Testing
- Daprodustat (GSK1278863)
- Where
- 2 sites in United States
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Chronic Myeloid Leukemia
TGRX-678 Pharmacokinetic Mass Balance
This is a pharmacokinetic study for [14C]TGRX-678 on mass balance to evaluate distribution, metabolism and excretion of TGRX-678, a tyrosine kinase inhibitor indicated for treatment of chronic myeloid leukemia.
- Trial name
- NCT06986772
- Testing
- [14C]TGRX-678
- Where
- China
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Shenzhen TargetRx Co., Ltd.
Blood Coagulation Disorders, Thrombotic Disorders
Determination of Fibrin Activity in Plasma on STA-R® Prototype
The purpose of the study is to give the proof of concept of the Fibrin structure assay on STA-R® prototype. It aims to identify the parameters which discriminate the pathologic from the normal population.
- Conditions
- Blood Coagulation Disorders, Thrombotic Disorders, Hemorrhagic Disorders, Trauma
- Trial name
- FAST (NCT02856789)
- Testing
- Routine hemostasis tests, Fibrin structure (FS), Thromboelastography (TEG)
- Where
- France
- Volunteers
- 913 people, healthy volunteers welcome
- Sponsor
- Diagnostica Stago R&D
Anemia, Iron Deficiencies
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CTX001 in Healthy Adults.
This study is testing CTX001 for certain conditions where the body does not have enough available iron or has difficulty storing or moving iron properly.
- Conditions
- Anemia, Iron Deficiencies, Chronic Kidney Disease
- Trial name
- NCT07577817
- Testing
- CTX001 With and Without Iron, CTX001 With Iron, CTX001 Multiple Dose
- Where
- Australia
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Cajal Therapeutics Inc.
Von Willebrand Diseases
Study of VGA039 in Healthy Volunteers and Patients With Von Willebrand Disease (VIVID)
The VIVID study is structured in a master protocol format comprised of multiple parts that evaluate intravenous (IV) and subcutaneous (SC) VGA039 in healthy volunteers and subjects with von Willebrand Disease (VWD) and other…
- Trial name
- NCT05776069
- Testing
- VGA039
- Where
- 25 sites in United States, Australia and 6 more
- Volunteers
- 116 people, healthy volunteers welcome
- Sponsor
- Vega Therapeutics, Inc
Chronic Myeloid Leukemia
TGRX-678 Phase I Oral Pharmacokinetic Study
A study evaluating the effects of food intake on the pharmacokinetic (PK) profiles of TGRX-678
- Trial name
- NCT06697899
- Testing
- TGRX-678
- Where
- China
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- Shenzhen TargetRx Co., Ltd.
Anaemia
Study to Assess the Pharmacokinetics of GSK1278863A Coadministered With a High Fat Meal or an Inhibitor of CYP2C8 (Gemfibrozil)
Study to Assess the Pharmacokinetics of GSK1278863A Coadministered with a High Fat Meal or an Inhibitor of CYP2C8 (gemfibrozil),]
- Trial name
- DDI (NCT01376232)
- Testing
- GSK1278863, GSK1278863 + food, Gemfibrozil
- Where
- India
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Sickle Cell Disease
A Phase I/II Study of ITU512 in Healthy Participants and Patients With Sickle Cell Disease
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary food effect of ITU512 as well as the fetal hemoglobin (HbF)-inducing capacity of ITU512.
- Trial name
- NCT06546670
- Testing
- ITU512
- Where
- 14 sites in United States, Brazil and 1 more
- Volunteers
- 161 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Methemoglobinemia, Congenital Methemoglobinemia
Safety, Tolerability, and Pharmacokinetic Study of Methylene Blue Following a 1 mg/kg Intravenous Dose in Healthy Adults
A Phase 1 trial to assess the single-dose safety, tolerability, and pharmacokinetic (PK) of Methylene Blue Injection, USP 1 mg/kg in healthy adult volunteers.
- Trial name
- NCT02478281
- Testing
- Methylene Blue
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- American Regent, Inc.
Hepatic Impairment
A Phase I Study to Investigate the Effect of Hepatic Impairment of AZD9550 and AZD6234
The purpose of this study is to examine the safety and tolerability of AZD6234 and AZD9550 in participants with hepatic impairment and participants with normal hepatic function.
- Trial name
- NCT07546760
- Testing
- AZD6234, AZD9550
- Where
- 4 sites in United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Hereditary Hemorrhagic Telangiectasia
A Study to Evaluate ALN-6400 in Healthy Volunteers and Patients With Hereditary Hemorrhagic Telangiectasia (HHT)
The purpose of this study is to: evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of single ascending doses of ALN-6400 in healthy volunteers evaluate the efficacy, safety, tolerability and PD of…
- Trial name
- InsigHHT (NCT06659640)
- Testing
- ALN-6400
- Where
- 16 sites in United States, Australia and 4 more
- Volunteers
- 89 people, healthy volunteers welcome
- Sponsor
- Alnylam Pharmaceuticals
Cutaneous T Cell Lymphoma, Mycosis Fungoides
A Phase 1, Open-label Study of the Absorption, Metabolism, Excretion of [14C]-Resminostat
Resminostat is a potent, orally available inhibitor of Class I, IIb and IV histone deacetylases (HDACs), including a pronounced activity against HDAC6.
- Conditions
- Cutaneous T Cell Lymphoma, Mycosis Fungoides, Sezary Syndrome
- Trial name
- NCT04955340
- Testing
- [14C]-resminostat
- Where
- United Kingdom
- Volunteers
- 5 people, healthy volunteers welcome
- Sponsor
- 4SC AG
Neutropenia
Biosimilarity Study of Subcutaneous Pegfilgrastim in Healthy Volunteers
This study will compare the pharmacokinetics and pharmacodynamics, after single subcutaneous application, in healthy men, between pegfilgrastim formulation, produced by Megalabs (test product) and Neulastim® (reference product)…
- Trial name
- NCT04873765
- Testing
- Pegfilgastrim Megalabs, Pegfilgastim Amgen
- Where
- Uruguay
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Megalabs
Thrombosis
A Study to Investigate Biomarkers After Single Doses of Anticoagulants in Healthy Young Male and Healthy Elderly Participants (MK-0000-216 AM1)
This is a study to investigate biomarkers after single oral doses of the anticoagulant agents dabigatran etexilate and rivaroxaban in healthy young male subjects and in healthy elderly subjects.
- Trial name
- NCT01379300
- Testing
- dabigatran etexilate, rivaroxaban
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Solid and Hematological Malignancies
Study to Assess the Effect of Food and Acid Reducing Agents on the Absorption of Capivasertib in Healthy Participants
This is a two-part, open-label, randomized, crossover study in healthy subjects (vasectomized males and women of non-childbearing potential), performed at 2 study centers
- Trial name
- NCT04944771
- Testing
- Capivasertib, Rabeprazole
- Where
- Germany
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Fetal and Neonatal Alloimmune Thrombocytopenia
Kinetics of Blood Platelets Transfused to Healthy Subjects
The current phase 0 trial is preceding the phase 1/2 trial of a newly developed drug, NAITgam, for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT) - a rare, but potentially very severe bleeding condition…
- Trial name
- NCT03561909
- Testing
- Platelet transfusion
- Where
- Germany
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Prophylix Pharma AS
Leucocytosis
Clinical Trial to Evaluate Pharmacokinetics, Pharmacodynamics and Safety of Leucostim® Compared to Neupogen®
BCD-002-1 is 1 phase clinical trial to evaluate pharmacokinetics, pharmacodynamics and safety of single-injection of Leucostim® to healthy volunteers compared to Neupogen®
- Trial name
- NCT02762799
- Testing
- Leucostim®, Neupogen®
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Biocad
Anaemia
Effects of GSK1278863A on Pulmonary Artery Pressure in Healthy Volunteers
This protocol is designed to explore whether short-term therapy with GSK1278863 affects PASP under normoxic and hypoxic conditions in healthy volunteers.
- Trial name
- NCT01673555
- Testing
- GSK1278863
- Where
- United States
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Healthy Volunteers Sickle Cell Disease, Thalassemia
A Research Study of the Effect of Etavopivat on Other Drugs in Healthy Participants
The study aims to test if a new medicine called etavopivat potentially affects other medicines in healthy participants. The purpose of the study is to investigate whether the use of etavopivat affects the breakdown and metabolism…
- Trial name
- NCT06813924
- Testing
- Etavopivat, Digoxin, Pitavastatin
- Where
- United States
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S